Expression of Livin and PlGF in human osteosarcoma is associated with tumor progression and clinical outcome

Sun,Kuo; Liao,Qi; Chen,Zenggan; Chen,Tongyi; Zhang,Jian

doi:10.3892/ol.2018.9239

Expression of Livin and PlGF in human osteosarcoma is associated with tumor progression and clinical outcome

Authors:
- Kuo Sun
- Qi Liao
- Zenggan Chen
- Tongyi Chen
- Jian Zhang
View Affiliations

Affiliations: Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Orthopedics, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
Published online on: July 31, 2018 https://doi.org/10.3892/ol.2018.9239
Pages: 4953-4960
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Baculoviral IAP repeat containing 7 (BIRC7/Livin/ML‑IAP/KIAP; referred to as Livin throughout the present study) and placental growth factor (PlGF) are not detectable in the majority of normal differentiated tissues, but are present in a number of types of cancer, including hepatocellular carcinoma, ovarian cancer and renal cell carcinoma. The aim of the present study was to assess the expression levels of Livin and PlGF in human osteosarcoma specimens and cell lines, and to analyze the functions of Livin and PIGF in the prognosis of osteosarcoma. The expression levels of Livin and PlGF in 48 osteosarcoma specimens and three osteosarcoma cells were determined using immunohistochemistry and reverse transcription‑quantitative polymerase chain reaction. The positivity rates of Livin and PlGF in osteosarcoma specimens were 58.3 and 60.4%, respectively, but were 0% in normal bone tissues. The expression levels of Livin and PlGF were increased in MG‑63 cells, compared with those in the other cell lines evaluated in the present study. In addition, the expression levels of Livin and PlGF were significantly associated with tumor diameter and Enneking staging, but were independent of tumor site, age and sex of patients. The expression level of Livin was not associated with PlGF. Furthermore, the 5‑year overall survival rate was decreased in the Livin or PlGF expression group, compared with that in the non‑expression group (P=0.034 and P=0.012, respectively). The expression levels of Livin and PlGF were independent prognostic factors for patients with osteosarcoma. The results of the present study demonstrated that Livin and PlGF may participate in the pathogenesis of osteosarcoma. Therefore, pharmacological inhibition of Livin or PlGF may provide a novel strategy for osteosarcoma treatment.

View Figures

View References

1	Pruksakorn D, Phanphaisarn A, Pongnikorn D, Daoprasert K, Teeyakasem P, Chaiyawat P, Katruang N and Settakorn J: Age standardized incidence rates and survival of osteosarcoma in northern thailand. Asian Pac J Cancer Prev. 17:3455–3458. 2016.PubMed/NCBI
2	Aznab M and Hematti M: Evaluation of clinical process in osteosarcoma patients treated with chemotherapy including cisplatin, adriamycin, ifosfamide, and etoposide and determination of the treatment sequels in a long-term 11-year follow-up. J Cancer Res Ther. 13:291–296. 2017. View Article : Google Scholar : PubMed/NCBI
3	PosthumaDeBoer J, Witlox MA, Kaspers GJ and van Royen BJ: Molecular alterations as target for therapy in metastatic osteosarcoma: A review of literature. Clin Exp Metastasis. 28:493–503. 2011. View Article : Google Scholar : PubMed/NCBI
4	Du MD, He KY, Qin G, Chen J and Li JY: Adriamycin resistance-associated prohibitin gene inhibits proliferation of human osteosarcoma MG63 cells by interacting with oncogenes and tumor suppressor genes. Oncol Lett. 12:1994–2000. 2016. View Article : Google Scholar : PubMed/NCBI
5	Yoon TM, Kim SA, Lee DH, Lee JK, Park YL, Lee KH, Chung IJ, Joo YE and Lim SC: Livin enhances chemoresistance in head and neck squamous cell carcinoma. Oncol Rep. 37:3667–3673. 2017. View Article : Google Scholar : PubMed/NCBI
6	Li CJ, Cong Y, Liu XZ, Zhou X, Shi X, Wu SJ, Zhou GX and Lu M: Research progress on the livin gene and osteosarcomas. Asian Pac J Cancer Prev. 15:8577–8579. 2014. View Article : Google Scholar : PubMed/NCBI
7	Hou Q, Li MY, Huang WT, Wei FF, Peng JP, Lou MW and Qiu JG: Association between three VEGF polymorphisms and renal cell carcinoma susceptibility: A meta-analysis. Oncotarget. 8:50061–50070. 2017. View Article : Google Scholar : PubMed/NCBI
8	Liang L, Yue Z, Du W, Li Y, Tao H, Wang D, Wang R, Huang Z, He N, Xie X, et al: Molecular imaging of inducible VEGF expression and tumor progression in a breast cancer model. Cell Physiol Biochem. 42:407–415. 2017. View Article : Google Scholar : PubMed/NCBI
9	Yan B, Kong M, Chen S and Chen YH: VEGF stimulation enhances Livin protein synthesis through mTOR signaling. J Cell Biochem. 111:1114–1124. 2010. View Article : Google Scholar : PubMed/NCBI
10	Chen L, Ren GS, Li F and Sun SQ: Expression of livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma. World J Gastroenterol. 14:5749–5754. 2008. View Article : Google Scholar : PubMed/NCBI
11	Pagani E, Ruffini F, Cappellini Antonini GC, Scoppola A, Fortes C, Marchetti P, Graziani G, D'Atri S and Lacal PM: Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness. Int J Oncol. 48:1581–1589. 2016. View Article : Google Scholar : PubMed/NCBI
12	Babkina IV, Osipov DA, Solovyov YN, Bulycheva IV, Machak GN, Aliev MD and Kushlinsky NE: Endostatin, placental growth factor, and fibroblast growth factors-1 and −2 in the sera of patients with primary osteosarcomas. Bull Exp Biol Med. 148:246–249. 2009. View Article : Google Scholar : PubMed/NCBI
13	Marrony S, Bassilana F, Seuwen K and Keller H: Bone morphogenetic protein 2 induces placental growth factor in mesenchymal stem cells. Bone. 33:426–433. 2003. View Article : Google Scholar : PubMed/NCBI
14	Mahmoodi F and Akrami H: PlGF knockdown decreases tumorigenicity and stemness properties of spheroid body cells derived from gastric cancer cells. J Cell Biochem. 118:851–859. 2017. View Article : Google Scholar : PubMed/NCBI
15	Incio J, Tam J, Rahbari NN, Suboj P, McManus DT, Chin SM, Vardam TD, Batista A, Babykutty S, Jung K, et al: PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. Clin Cancer Res. 22:2993–3004. 2016. View Article : Google Scholar : PubMed/NCBI
16	Enneking WF, Spanier SS and Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 106–120. 1980.PubMed/NCBI
17	Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58:5071–5074. 1998.PubMed/NCBI
18	Wang YF, Shen JN, Xie XB, Wang J and Huang G: Expression change of ezrin as a prognostic factor in primary osteosarcoma. Med Oncol. 28 Suppl 1:S636–S643. 2011. View Article : Google Scholar : PubMed/NCBI
19	Sampson VB, Vetter NS, Zhang W, Patil PU, Mason RW, George E, Gorlick R and Kolb EA: Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma. Oncotarget. 7:86594–86607. 2016. View Article : Google Scholar : PubMed/NCBI
20	Horie R, Nakamura O, Yamagami Y, Mori M, Nishimura H, Fukuoka N and Yamamoto T: Apoptosis and antitumor effects induced by the combination of an mTOR inhibitor and an autophagy inhibitor in human osteosarcoma MG63 cells. Int J Oncol. 48:37–44. 2016. View Article : Google Scholar : PubMed/NCBI
21	Saleem M, Qadir MI, Perveen N and Ahmad B, Saleem U, Irshad T and Ahmad B: Inhibitors of apoptotic proteins: New targets for anticancer therapy. Chem Biol Drug Des. 82:243–251. 2013. View Article : Google Scholar : PubMed/NCBI
22	Liu GH, Wang C and Ding ZY: Overexpression of the truncated form of Livin reveals a complex interaction with caspase-3. Int J Oncol. 42:2037–2045. 2013. View Article : Google Scholar : PubMed/NCBI
23	Lin X, Li HR, Lin XF, Yu ME, Tu XW, Hua ZD, Lin M, Xu NL, Han LL and Chen YS: Silencing of Livin inhibits tumorigenesis and metastasis via VEGF and MMPs pathway in lung cancer. Int J Oncol. 47:657–667. 2015. View Article : Google Scholar : PubMed/NCBI
24	Zhuang L, Shen LD, Li K, Yang RX, Zhang QY, Chen Y, Gao CL, Dong C, Bi Q, Tao JN, et al: Inhibition of livin expression suppresses cell proliferation and enhances chemosensitivity to cisplatin in human lung adenocarcinoma cells. Mol Med Rep. 12:547–552. 2015. View Article : Google Scholar : PubMed/NCBI
25	Nedelcu T, Kubista B, Koller A, Sulzbacher I, Mosberger I, Arrich F, Trieb K, Kotz R and Toma CD: Livin and Bcl-2 expression in high-grade osteosarcoma. J Cancer Res Clin Oncol. 134:237–244. 2008. View Article : Google Scholar : PubMed/NCBI
26	Guan HP, Sun JZ, Feng XL, Chen JS, Chen FJ, Cheng XF, Liu XW and Ni B: Effects of RNA interference-mediated knockdown of livin and survivin using monomethoxypolyethylene glycol-chitosan nanoparticles in MG-63 osteosarcoma cells. Mol Med Rep. 13:1821–1826. 2015. View Article : Google Scholar : PubMed/NCBI
27	Ségaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal C and Heymann D: Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer. 137:73–85. 2015. View Article : Google Scholar : PubMed/NCBI
28	Liu JQ, Bai X, Duan DC and Dou AX: Role of five small nucleotide polymorphisms in the VEGF gene on the susceptibility to osteosarcoma and overall survival of patients. Oncol Lett. 10:1481–1486. 2015. View Article : Google Scholar : PubMed/NCBI
29	Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, et al: Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med. 9:936–943. 2003. View Article : Google Scholar : PubMed/NCBI
30	Ribatti D: The discovery of the placental growth factor and its role in angiogenesis: A historical review. Angiogenesis. 11:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
31	Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, et al: Anti-PlGF inhibits growth of VEGF(R)-inhibitor resistant tumors without affecting healthy vessels. Cell. 131:463–475. 2007. View Article : Google Scholar : PubMed/NCBI
32	Meng FJ, Xiao SX, Zhang Y, Wang W, Wang B and Fan XY: Prognostic significance of placenta growth factor expression in patients with multiple cancers: A meta-analysis. Int J Clin Exp Med. 8:12726–12735. 2015.PubMed/NCBI
33	Taylor AP and Goldenberg DM: Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Mol Cancer Ther. 6:524–531. 2007. View Article : Google Scholar : PubMed/NCBI
34	Clover J and Gowen M: Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype? Bone. 15:585–591. 1994. View Article : Google Scholar : PubMed/NCBI
35	Fogh J, Wright WC and Loveless JD: Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst. 58:209–214. 1977. View Article : Google Scholar : PubMed/NCBI
36	Pontén J and Saksela E: Two established in vitro cell lines from human mesenchymal tumours. Int J Cancer. 2:434–447. 1967. View Article : Google Scholar : PubMed/NCBI
37	Lisignoli G, Toneguzzi S, Cattini L, Pozzi C and Facchini A: Different expression pattern of cytokine receptors by human osteosarcoma cell lines. Int J Oncol. 12:899–903. 1998.PubMed/NCBI
38	Cifuentes M, García MA, Arrabal PM, Martínez F, Yañez MJ, Jara N, Weil B, Domínguez D, Medina RA and Nualart F: Insulin regulates GLUT1-mediated glucose transport in MG-63 human osteosarcoma cells. J Cell Physiol. 226:1425–1432. 2011. View Article : Google Scholar : PubMed/NCBI